Loading organizations...
Key people at Oxbridge Biotech Roundtable.
The Oxbridge Biotech Roundtable (OBR) operates as a global platform connecting academic researchers and industry innovators within the life sciences and healthcare sectors. Its core offering involves facilitating interaction, collaboration, and the translation of ideas from scientific discovery to practical application. The organization works to bridge existing gaps and dismantle barriers that traditionally separate these distinct domains, fostering a more integrated ecosystem.
The initiative was co-founded in 2011 in Oxford, UK, by Daniel Perez and Thomas von Erlach. Their foundational insight stemmed from recognizing a significant disconnect between groundbreaking academic research and its industrial potential, coupled with a lack of structured avenues for effective collaboration. Perez and von Erlach established the OBR to address this, drawing on their backgrounds to cultivate a network poised for interdisciplinary engagement.
The platform serves a diverse audience, including academics, students across various disciplines, industry professionals, and burgeoning bio-entrepreneurs. OBR's overarching vision is to function as a worldwide hub for innovators, proactively promoting entrepreneurial endeavors and accelerating progress in life sciences and health. It seeks to achieve this by consistently connecting individuals with varied expertise and perspectives.
Oxbridge Biotech Roundtable (OBR) is a non-profit platform founded in 2011 that connects academic innovators with industry professionals to advance life sciences and healthcare ideas.[1][3][4] Its mission centers on fostering conversations between academia and industry, building a global network across the UK and US to translate research into viable ventures.[1][2][5] OBR's investment philosophy emphasizes entrepreneurship through initiatives like the OneStart accelerator, co-founded with SR One in 2012, which supports early-stage healthcare startups via competitions, bootcamps, and mentorship for innovators under 36 with limited funding.[1][2]
OBR impacts the startup ecosystem by bridging transatlantic biotech communities, partnering with organizations like MassBio and corporate VCs such as GlaxoSmithKline's SR One, and running high-profile events like the OneStart Idea Competition, which awarded £100,000 to winners like Puridify Ltd. in 2013.[1][2] With chapters in the UK and US, it catalyzes innovation by providing resources, industry exposure, and support to move academic concepts toward commercialization.[1][3]
OBR emerged in 2011 from a collaborative effort by students at Oxford and Cambridge Universities in the UK, aiming to link academic talent with industry leaders in life sciences.[1][5] Daniel (Dan) Perez, a key founder and later CEO, drove its expansion alongside co-founders, evolving it from a campus-focused discussion forum into a global network with US chapters.[1][2] Early momentum came from partnerships, notably launching the OneStart program in 2012 with SR One, GlaxoSmithKline's venture arm, which drew 100 entries for its inaugural £100,000 competition and selected finalists for pitches to top VCs and pharma executives.[1]
Pivotal moments included semi-finalist bootcamps for business plan development and the 2013 finale at London's Grand Connaught Rooms, where UCL spinout Puridify won and LipoPep took runner-up.[1] By partnering with MassBio around this time, OBR extended its reach to Massachusetts, strengthening UK-US ties and supporting young bio-entrepreneurs.[2]
OBR rides the trend of academia-industry convergence in biotech, where translational research demands strong bridges amid rising demand for disruptive healthcare solutions.[1][2][3] Timing aligns with post-2010s biotech boom, fueled by venture interest in early-stage ideas and global talent mobility between UK hubs like Oxford/Cambridge and US clusters like Boston.[2][5] Market forces favoring OBR include pharma's push for innovation partnering (e.g., Roche, GSK involvement) and accelerators' role in derisking startups amid funding gaps for pre-seed ventures.[1]
It influences the ecosystem by democratizing access—empowering students and early teams via free resources and exposure—while amplifying European bio-entrepreneurship globally, as evidenced by OneStart's worldwide applications.[1][2] This positions OBR as a key enabler in a landscape where 700+ MassBio members and similar networks seek diverse, high-potential ideas.[2]
OBR's influence will likely grow through scaling OneStart and deepening US-UK partnerships, capitalizing on AI-driven drug discovery and personalized medicine trends that demand agile academic-industry links.[1][2] Expect expanded virtual events and corporate tie-ups to sustain momentum, potentially influencing more spinouts amid biotech's projected 2026+ funding resurgence. As a nimble connector rather than a funder, OBR remains uniquely positioned to nurture the next wave of healthcare disruptors, evolving from roundtables to a cornerstone of global bio-entrepreneurship.
Key people at Oxbridge Biotech Roundtable.
